|
Status |
Public on Jun 12, 2016 |
Title |
DMSO Rep 1 |
Sample type |
SRA |
|
|
Source name |
MV4;11_DMSO
|
Organism |
Homo sapiens |
Characteristics |
tissue source: peripheral blood cell line: MV4;11 cell type: Mixed lineage leukemia (MLL) fusion protein (FP) leukemia cell line treated with: 0.1% DMSO
|
Treatment protocol |
Cell lines were grown in 0.1% DMSO, 500nM of I-BET151 and/or 5uM of SGC0946
|
Growth protocol |
Cell lines were grown in RPMI-1640 supplemented with 20% fetal calf serum, penicillin (100 units/mL) and streptomycin (100 ug/mL)
|
Extracted molecule |
polyA RNA |
Extraction protocol |
RNA was prepared using the Qiagnen RNeasy kit TruSeq RNA Sample Preparation protocol (Illumina)
|
|
|
Library strategy |
RNA-Seq |
Library source |
transcriptomic |
Library selection |
cDNA |
Instrument model |
Illumina HiSeq 2000 |
|
|
Description |
Replicate 1
|
Data processing |
Illumina Casava1.8.2 software was used for basecalling. Reads were aligned to the human genome (G1k V37) using tophat2 and bowtie2 Reads were assigned to genes using htseq-count. Differential expression was calculated using edgeR. Genes with a false discovery rate below 0.05 and a foldāchange greater than 2 were considered significantly differentially expressed. Genome_build: hg19 Supplementary_files_format_and_content: tab-delimited text file of normalised expression values for all Samples
|
|
|
Submission date |
Aug 06, 2015 |
Last update date |
May 15, 2019 |
Contact name |
Mark Dawson |
E-mail(s) |
mark.dawson@petermac.org
|
Organization name |
Peter MacCallum Cancer Centre
|
Street address |
305 Grattan Street
|
City |
Melbourne |
State/province |
VIC |
ZIP/Postal code |
3000 |
Country |
Australia |
|
|
Platform ID |
GPL11154 |
Series (2) |
GSE71777 |
RNASeq of MV4;11 cell treated with DMSO, I-BET, SGC0946 and combination of I-BET and SGC0946 |
GSE71780 |
Functional interdependency of BRD4 and DOT1L in MLL leukaemia |
|
Relations |
SRA |
SRX1134753 |
BioSample |
SAMN03979592 |